Private finance: Loop Medical, OneProjects, AceCann, Bisu, Chance Pharmaceuticals, Rejuvenate Biomed

Belgium: Rejuvenate Biomed, a biomedical company developing combination drugs for age-related diseases, has raised €15.7m (US$18.1m) in Series B funding led by Rejuveron Life Sciences and Vesalius Biocapital. Funds will be used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure). Rejuvenate is…

You must be a HMI Subscriber to view this content.

Subscribe Now »